On July 8th members of the OBIO team spent the day meeting various stakeholders across Hamilton.
On June 25th, OBIO hosted 'Is the Price Right? Pricing Your Innovative Healthcare Product' which featured a presentation by Amy Siegel (C-Founder, S2N Health).
On June 10th, OBIO hosted a Pitches & Pitchers event, supported by Lumira Ventures and Whitecap Venture Partners.
On May 30th 2019, Martin Musiol (RA/QA Manager, IPD Inc) led “The Keys to Quality: Introduction to Good Manufacturing Practices, Quality Management Systems, and Working in Regulated Environments.”
On May 13th, OBIO hosted the 2019 Queen’s Park Health Science Industry Showcase which attracted over 100 attendees, including Ministers, MPPs, government officials and health science industry leaders who came to see the latest in health care innovation from our displaying companies.
On April 25, one day before World Intellectual Property day, together with Bereskin & Parr, OBIO held a workshop entitled “Game Planning to Build Strong IP”. The workshop focused on two important aspects of IP: IP strategy and patent searching.
OBIO hosted 'Going Virtual for Product Development, Manufacturing & Clinical Trials' workshop on Tuesday, March 5th, which featured three industry professionals who discussed virtual operations and shared advice on how to be successful as a ‘virtual’ company.
Picking up where we left off last week, the second day of the 2019 Niagara Investment Summit (February 20th-22nd, 2019) continued on the first day’s theme: bringing together CEOs and senior executives from Canada’s most innovative health science companies with investors and strategics in beautiful Niagara-on-the-Lake.
The OBIO 2019 Niagara Investment Summit, held in historic Niagara-on-the-Lake from February 20th through 22nd, brought together CEOs and senior executives representing Canadian health science companies from Halifax to Vancouver, global investors and venture capitalists, and health science industry leaders for two panels of company presentations, one-on-one meetings, panel discussions and keynote speakers.
On February 26th, OBIO hosted Jasmin Ganie-Hobbs (Director Tech Finance, BDC) and Antonio Lopes (Global Accounts Director, EDC) who spoke about “How BDC and EDC Can Help Your Business.”
OBIO’s recent Cross Border Investing panel on January 31, 2019, hosted by Osler Hoskin & Harcourt LLP and moderated by Gail Garland (CEO, OBIO), featured David Young (CEO, Kisoji Biotechnology), Mike Cooke (CEO, AmacaThera) and Chad Bayne (Partner, Osler) answering questions on their experiences raising money for Canadian companies from international investors.
On January 24th, OBIO’s C-Suite Pub Night networking event was attended by over 50 CEOs and senior health science company executives.
On November 28th, OBIO held our 2018 Annual General Meeting at the offices of Norton Rose Fulbright. The exciting event featured Nik Nanos, our keynote speaker whose presentation Global Disruption: How to Make Decisions in an Age When Truth and Data are No Longer Enough to Persuade scanned recent global political experiences and explained the outsized influence of the margins, both on electoral outcomes as well as the impact for your company.
Last week, OBIO announced the successful completion of the OBIO Canadian Health Investment Showcase in New York City. Check out this recap and photo gallery of the event.
On October 3rd, OBIO hosted a CEO2CEO event attended by over 30 CEOs and senior health science company executives
On September 18th, OBIO organized a workshop with two industry experts and provided the CFO perspective on budgeting for start-up and growing health science companies.
John Jordan (CFO, RNA Diagnostics) and Jim Cooke (Partner, Stoneybridge Partners) addressed 3 main areas – how to build a robust budget, how to present a budget to the board and to investors and how to manage a budget.
On Wednesday, September 5th, OBIO hosted Toshio Sugano, the Chief Investment Officer of the Biomedical Development Board of Taiwan, who met with a collection of Canada’s most esteemed investors and some of its highest potential health science companies.